DSMB hits pause on Voy­ager's Neu­ro­crine-part­nered Parkin­son's gene ther­a­py

Voy­ager Ther­a­peu­tics’ clin­i­cal plans have hit an­oth­er snag.

The Cam­bridge biotech dis­closed in their third quar­ter earn­ings Mon­day that the da­ta safe­ty and mon­i­tor­ing board has rec­om­mend­ed halt­ing en­roll­ment on their piv­otal Phase II tri­al test­ing their lead gene ther­a­py for Parkin­son’s dis­ease. Voy­ager and their part­ner Neu­ro­crine had al­ready paused en­roll­ment be­cause of Covid-19, but will now post­pone plans to re­sume the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.